

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: He et al.

Attorney Docket No.: PF150D2

Application Serial No.: Unassigned

Art Unit: Unassigned

Parent Filed: Herewith

Examiner: Unassigned

Title: Human Prostatic Specific Reductase



**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-AR listed on the attached Form PTO/SB/08.

Copies of references AA-AQ were submitted by Applicants or cited by the Examiner in connection with United States Patent Application Serial No. 09/123,386, filed July 27, 1998, and United States Patent Application Serial No. 08/464,400, filed June 5, 1995 (now U.S. Patent No. 5,786,204), to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), Applicants respectfully refer the Examiner to the files of the prior applications for copies of references AA-AQ.

A copy of reference AR is submitted herewith.

References AO and AP were cited in a Supplementary Partial European Search Report (ref. AQ) in the European counterpart of prior Application No. PCT/US95/01827.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application and consider the information contained therein during the prosecution of this application.


Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the materials identified above and that they be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(1), since this Information Disclosure Statement is being submitted within three months of (i.e., concurrently with) the filing of the instant application, no fee is believed due in connection with the submission of this Statement. However, the Patent Office is authorized to charge any fee or credit any overpayment in connection with this submission to our Deposit Account No. 08-3425.

Respectfully submitted,

Dated: December 19, 2001

  
Jonathan L. Klein  
Attorney for Applicants

Reg. No. 41,119

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: (301) 251-6015

JKE/CCB/ba

Please type a plus sign (+) inside this box ?



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b> (use as many sheets as necessary)				Complete If Known	
				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	HE et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	PF150D2
U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document Kind Code <sup>2</sup> Number (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	4,800,159	CETUS CORP.	01-24-89	
	AB	5,420,245	BOARD OF REGENTS, THE UNIV. OF TEXAS	05-30-95	
OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	AC	RIEGMAN et al., "Molecular Cloning and Characterization of Novel Prostate Antigen cDNA's," <i>Biochem. and Biophys. Res. Comm.</i> , 155(1):181-188 (August 30, 1988)			
	AD	ISRAELI et al., "Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen," <i>Cancer Research</i> , 53:227-230 (January 15, 1993)			
	AE	ISRAELI et al., "Sensitive Nested Reverse Transcription Polymerase Chain Reaction Detection of Circulating Prostatic Tumor Cells: Comparison of Prostate-specific Membrane Antigen and Prostate-specific Antigen-based Assays," <i>Cancer Research</i> , 54:6306-6310 (December 15, 1994)			
	AF	DEGUCHI et al., "Detection of Micrometastatic Prostate Cancer Cells in Lymph Nodes by Reverse Transcriptase-Polymerase Chain Reaction," <i>Cancer Research</i> , 53:5350-5354 (November 15, 1993)			
	AG	MATOBA et al., "The addition of 5'-coding information to a 3'-directed cDNA library improves analysis of gene expression," <i>Gene</i> , 146:199-270 (September 1994)			
	AH	GenBank Accession No. D17020, MATOBA et al., "Human HepG2 partial cDNA, clone hmd3a07m5" (December 1, 1994)			
	AI	LEWIN, "Genes V" (Oxford University Press), page 648 (1994)			
	AJ	NIERMAN et al., "ATCC/NIH Repository Catalogue of Human and Mouse DNA Probes and Libraries, 1-58 (1994)			
	AK	MORENO et al., "Detection of Hematogenous Micrometastasis in Patients with Prostate Cancer," <i>Cancer Research</i> , 52:6110-6112 (1992)			
	AL	KLEINSMITH et al., Textbook 2nd Ed. "Principles of Cell and Molecular Biology," (ISBN 0-06 5004 04-3, page 528 (1995 2nd)			
	AM	GenBank Accession No. R20331; HILLIER et al. (April 17, 1995)			
	AN	GenBank Accession No. R12745, HILLIER et al. (April 12, 1995)			
	AO	THIGPEN et al., "Molecular Genetics of Steroid 5 $\alpha$ -Reductase 2 Deficiency," <i>J. Clinical Invest.</i> , 90:799-809 (September 1992)			
	AP	AKALU et al., "Somatic Mutations at the SRD5A2 Locus Encoding Prostatic Steroid 5 $\alpha$ -Reductase During Prostate Cancer Progression," <i>J. Urology</i> , 161:1355-1358 (April 1999)			
	AQ	Supplementary Partial European Search Report, Application No. EP95911712 (August 3, 2000)			
	AR	LIN et al., "Prostate Short-Chain Dehydrogenase Reductase 1 (PSDR1): A New Member of the Short-Chain Steroid Dehydrogenase/Reductase Family Highly Expressed in Normal and Neoplastic Prostate Epithelium," <i>Cancer Research</i> , 61:1611-1618 (February 15, 2001)			
Examiner		Date Considered			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.